A review of erlotinib and its clinical use

被引：85

作者：

Tang, PA

Tsao, MS

Moore, MJ

机构：

[1] Univ Toronto, Dept Pathol, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 02期

关键词：

erlotinib; non-small cell lung cancer; pancreatic cancer; squamous cell cancer of the head and neck;

D O I：

10.1517/14656566.7.2.177

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth factor receptor. Encouraging activity as a single agent and in corn bination with other targeted agents has been demonstrated in Phase 11 trials in many tumour types. Erlotinib has an established role in the treatment of advanced, refractory non-small cell lung cancer-based on a pivotal trial demonstrating a survival advantage over best supportive care. In a Phase III trial, the addition of erlotinib to gemcitabine improved survival in advanced pancreatic cancer. The toxicity profile of erlotinib includes diarrhoea and rash, with no haematological side effects. Predictive factors for response include the presence of a rash, epidermal growth factor receptor expression and mutation status. This article reviews the current clinical status of erlotinib.

引用

页码：177 / 193

页数：17

共 111 条

[1]

ABBAS R, 2003, J CLIN ONCOL, V2, P137

[2]

Amann J, 2005, CANCER RES, V65, P226

[3]

[Anonymous], 2003, P AM SOC CLIN ONCOL

[4] Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[5] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[6] Current perspectives on HER2 testing:: A review of national testing guidelines [J].

Bilous, M ;

Dowsett, M ;

Hanna, W ;

Isola, J ;

Lebeau, A ;

Moreno, A ;

Penault-Llorca, F ;

Rüschoff, J ;

Tomasic, G ;

de Vijver, MV .

MODERN PATHOLOGY, 2003, 16 (02) :173-182

[7]

Blaszkowsky LS, 2005, J CLIN ONCOL, V23, p332S

[8]

Brewer CJ, 2005, J CLIN ONCOL, V23, p130S

[9]

Britten CD, 2004, J CLIN ONCOL, V22, p206S

[10] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

← 1 2 3 4 5 6 7 8 9 10 →